Abstract:Neuropathic pain is a challenge for physicians and basic science researchers, because it often does not respond to routine treatment. The administration of morphine has been considered one of the effective recommended treatments, but its wide application is limited because of the development of antinociceptive tolerance. In general, basic science studies focus on neuropathic pain and morphine tolerance separately. However, we tried to investigate the effect of microglial activation on morphine tolerance in spinal nerve ligation (SNL) rats during the maintenance period of neuropathic pain. This study produced the following results. The morphine tolerance model in neuropathic pain was established by repeated administration of morphine twice daily (10mg/kg s.c) in the maintenance period of SNL rats. Minocycline, the microglial activation inhibitor, was given once daily (30mg/kg, i.p.) at different time-points. The CD11b protein level was measured by western blot to monitor microglial activation. Rats' mechanical allodynia was assessed using the 50% paw withdrawal threshold, and the tail antinociception was determined using the percentage of the maximal possible antinociceptive effect. First, the repeated administration of morphine induced the development of antinociceptive tolerance during the maintenance period of neuropathic pain. Second, during the development of morphine tolerance, microglial activation, which is related to the analgesic effect of morphine, decreased in the first few days, but this pattern was reversed in the following days with the development of morphine tolerance. Third, the repeated administration of minocycline, a microglial activation inhibitor, did not influence the antinociceptive effect of a single dose of morphine. Fourth, the pre-administration of minocycline can delay the development of morphine tolerance, but repeated minocycline administration cannot reverse existing morphine tolerance. We concluded that microglial activation contributes to the morphine tolerance of SNL rats in the maintenance period of neuropathic pain, and that minocycline delays the development of morphine tolerance, but does not reverse existing morphine tolerance during the maintenance period of neuropathic pain in rats. These findings might be useful for clinical pain management.

Minocycline as a promising therapeutic strategy for chronic pain

Mesoporous Silica Particles As a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy.

A minocycline derivative reduces nerve injury-induced allodynia, LPS-induced prostaglandin E2 microglial production and signaling via toll-like receptors 2 and 4

Minocycline Attenuates Mechanical Allodynia and Expression of Spinal NMDA Receptor 1 Subunit in Rat Neuropathic Pain Model

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Post-injury Administration of Minocycline: an Effective Treatment for Nerve-Injury Induced Neuropathic Pain

Antimicrobial therapies for chronic pain (part 1): analgesic mechanisms

Minocycline‐induced Reduction of Brain‐derived Neurotrophic Factor Expression in Relation to Cancer‐induced Bone Pain in Rats

Minocycline enhances the effectiveness of nociceptin/orphanin FQ during neuropathic pain

Wnt signaling: A prospective therapeutic target for chronic pain

Analgesic Nanomedicines for the Treatment of Chronic Pain

PD-1: A New Candidate Target for Analgesic Peptide Design

Intrathecal administration of MCRT produced potent antinociception in chronic inflammatory pain models via μ-δ heterodimer with limited side effects

Involvement of pro- and antinociceptive factors in minocycline analgesia in rat neuropathic pain model

The prospects of minocycline in multiple sclerosis.

Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies

MCP-1 : A potential candidate for pain management

Minocycline Can Delay the Development of Morphine Tolerance, but Cannot Reverse Existing Tolerance in the Maintenance Period of Neuropathic Pain in Rats

Monoclonal antibodies for chronic pain: A practical review of mechanisms and clinical applications

Combination of Tramadol with Minocycline Exerted Synergistic Effects on a Rat Model of Nerve Injury-Induced Neuropathic Pain.

The Microglial Activation Inhibitor Minocycline, Used Alone and in Combination with Duloxetine, Attenuates Pain Caused by Oxaliplatin in Mice